Share on StockTwits

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “outperform” rating reaffirmed by analysts at Oppenheimer in a research report issued to clients and investors on Thursday. They currently have a $35.00 price target on the stock, down from their previous price target of $40.00. Oppenheimer’s price target would indicate a potential upside of 30.89% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of ANI Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday, July 8th. They now have a $40.60 price target on the stock. Finally, analysts at Roth Capital raised their price target on shares of ANI Pharmaceuticals from $36.00 to $38.00 in a research note on Tuesday, May 6th.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded up 4.37% on Thursday, hitting $26.74. The stock had a trading volume of 342,160 shares. ANI Pharmaceuticals has a one year low of $5.99 and a one year high of $38.74. The stock’s 50-day moving average is $33.36 and its 200-day moving average is $30.00. The company has a market cap of $301.7 million and a price-to-earnings ratio of 184.32.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings data on Monday, May 5th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.01. The company had revenue of $10.90 million for the quarter, compared to the consensus estimate of $11.40 million. During the same quarter in the previous year, the company posted ($0.18) earnings per share. The company’s revenue for the quarter was up 94.6% on a year-over-year basis. Analysts expect that ANI Pharmaceuticals will post $1.17 EPS for the current fiscal year.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals.

Receive News & Ratings for ANI Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.